← ANALYST RATINGS · TIPRANKS
Immunome (IMNM): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $38.75, the highest $40.00, the lowest $35.00. The average is +135.3% from the last price of $16.47.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $17.00 → $16.50−2.9% | Hold | +0.2% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $16.00 → $15.50−3.1% | Sell | −5.9% | Downgrade | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $17.00 → $16.00−5.9% | Hold | −2.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $17.00 → $16.00−5.9% | Hold | −2.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $17.00 → $16.00−5.9% | Hold | −2.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $17.50 → $17.00−2.9% | Hold | +3.2% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Sharon Zackfia★★★★★★★★★★#4054 · hits 44% · avg +3.0% | William Blair | $35.00 | Buy | +112.5% | Initiated | 15.10.26on TipRanks Oct 16 05:55 | +0.9%next day −4.2% | ↗ |
| Dara Azar★★★★★★★★★★#9877 · hits 33% · avg −5.2% | Stifel Nicolaus | $24.00 | Hold | +45.7% | Reiterated | 06.10.26on TipRanks 06:55 | −9.3%next day −0.9% · 5 days −8.8% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $40.00 | Buy | +142.9% | Reiterated | 05.10.26on TipRanks 12:45 | +0.6%next day −9.3% · 5 days −10.0% | ↗ |
| Lukas Shumway★★★★★★★★★★#6090 · hits 67% · avg +8.8% | Barclays | $36.00 | Buy | +118.6% | Reiterated | 01.10.26on TipRanks 05:15 | −3.1%next day −0.7% · 5 days −8.9% | ↗ |
| Matthew Venezia★★★★★★★★★★#10510 · hits 33% · avg −7.8% | Alliance Global Partners | $32.00 | Buy | +94.3% | Initiated | 21.09.26on TipRanks 07:10 | +3.0%next day +2.7% · 5 days −12.5% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $40.00 | Buy | +142.9% | Reiterated | 11.09.26on TipRanks Sep 10 10:35 | −3.8%next day −2.1% · 5 days −4.8% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $35.00 | Buy | +112.5% | Reiterated | 12.08.26on TipRanks Aug 13 07:10 | +6.4%next day −6.3% · 5 days +7.0% | ↗ |
| Unknown Analyst | Wedbush | $31.00 → $35.00+12.9% | Buy | +112.5% | Reiterated | 12.08.26on TipRanks 09:56 | +6.4%next day −6.3% · 5 days +7.0% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $40.00 | Buy | +142.9% | Reiterated | 12.08.26on TipRanks 09:45 | +6.4%next day −6.3% · 5 days +7.0% | ↗ |
| Adam Vogel★★★★★★★★★★#1113 · hits 79% · avg +38.0% | Craig-Hallum | $36.00 | Buy | +118.6% | Reiterated | 12.08.26on TipRanks 09:35 | +6.4%next day −6.3% · 5 days +7.0% | ↗ |
| Supawat Thongthip★★★★★★★★★★#6413 · hits 70% · avg +6.4% | Truist Financial | $37.00 → $38.00+2.7% | Buy | +130.7% | Reiterated | 12.08.26on TipRanks 07:35 | +6.4%next day −6.3% · 5 days +7.0% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $33.00 | Buy | +100.4% | Reiterated | 12.08.26on TipRanks 07:05 | +6.4%next day −6.3% · 5 days +7.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 11.08.26on TipRanks Aug 12 01:20 | +2.5%next day +6.4% · 5 days +5.4% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Buy | — | Reiterated | 29.06.26on TipRanks Jun 30 06:15 | +3.8%next day −0.1% · 5 days +15.0% | ↗ |
| Chad Messer★★★★★★★★★★#9258 · hits 37% · avg −0.2% | Lake Street | $30.00 | Buy | +82.1% | Reiterated | 01.06.26on TipRanks 10:25 | −5.1%next day −7.1% · 5 days −7.9% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $37.00 → $33.00−10.8% | Buy | +100.4% | Reiterated | 15.05.26on TipRanks 21:20 | −4.6%next day −0.5% · 5 days +8.5% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $35.00 | Buy | +112.5% | Reiterated | 13.05.26on TipRanks May 14 09:15 | −2.7%next day −1.6% · 5 days −2.9% | ↗ |
| Sudan Loganathan★★★★★★★★★★#1955 · hits 65% · avg +22.0% | Stephens | $30.00 | Buy | +82.1% | Assigned | 04.03.26on TipRanks 07:25 | +3.8%next day −6.4% · 5 days −3.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Immunome
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $35.36 at a price of $21.51 (+64.4%); now: $35.33 at $16.47 (+114.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 12 | 14 | 7 | 6 | 3 |
| Buy | 3 | 2 | 2 | 6 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.60 (from $-0.71 to $-0.41). Last quarter: $-0.65.
Sales
Next quarter’s sales estimate — $0M (from $0M to $2M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Immunome
- CEO: Clay Siegall
- Employees: 247
- 18702 North Creek Parkway, Bothell, WA, 98011, US
- www.immunome.com
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Data from the stock’s TipRanks forecast page, read 35 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗